SPDR S&P Pharmaceuticals ETF
XPH
XPH
60 hedge funds and large institutions have $204M invested in SPDR S&P Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% less funds holding
Funds holding: 61 → 60 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Holders
60
Holding in Top 10
–
Calls
$296K
Puts
$2K
Top Buyers
| 1 | +$31.7M | |
| 2 | +$27.6M | |
| 3 | +$15.7M | |
| 4 |
Goldman Sachs
New York
|
+$6.15M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.15M |
Top Sellers
| 1 | -$13.9M | |
| 2 | -$2.26M | |
| 3 | -$1.16M | |
| 4 |
Wells Fargo
San Francisco,
California
|
-$795K |
| 5 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$638K |